Maravai Lifesciences Holdings (MRVI) Accumulated Expenses (2020 - 2026)

Maravai Lifesciences Holdings' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $28.6 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 35.77% year-over-year to $28.6 million; the TTM figure through Mar 2026 stood at $28.6 million (down 35.77% YoY), while the FY2025 annual figure was $36.6 million, down 7.6% from the prior year.
• Accumulated Expenses was $28.6 million for Q1 2026 at Maravai Lifesciences Holdings, down from $36.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $70.1 million in Q1 2023 to a low of $28.6 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $46.4 million across 5 years, with a median of $44.6 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses jumped 116.18% in 2023, then plunged 49.47% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $53.4 million in 2022, then gained by 12.86% to $60.2 million in 2023, then plunged by 34.3% to $39.6 million in 2024, then retreated by 7.6% to $36.6 million in 2025, then declined by 21.66% to $28.6 million in 2026.
• The last three Accumulated Expenses figures came in at $28.6 million (Q1 2026), $36.6 million (Q4 2025), and $48.1 million (Q3 2025), per Business Quant data.